Fundz

Mitsubishi Backs Pharmenable In £6M Pre-Series A

PRIVATEMay 22, 2023

Amount Raised

£6 Million

Round Type

Pre-Series A

CambridgeBiotechnologyHealth Care

Investors

Mitsubishi Tanabe Pharma GroupMP Healthcare

Description

Drug discovery startup PharmEnable has secured $7.5m (£6m) in a pre-Series A raise led by Mitsubishi Tanabe Pharma Group’s venture capital division, MP Healthcare.

Quick answer

PharmEnable raised £6 Million in a Pre-Series A round, dated May 22, 2023. Investors: Mitsubishi Tanabe Pharma Group and MP Healthcare. PharmEnable is based in Cambridge, Maryland, United States.

How much did PharmEnable raise?
PharmEnable raised £6 Million in a Pre-Series A round on May 22, 2023.
Who invested in PharmEnable?
Mitsubishi Tanabe Pharma Group and MP Healthcare are named as investors in this round.
What does PharmEnable do?
PharmEnable is a Cambridge (UK) based drug discovery company, using a combination of medicinal chemistry and AI computational approaches to design the next generation of specific and cost-efficient small molecule drugs.
Where is PharmEnable based and how big is it?
PharmEnable is based in Cambridge, Maryland, United States.
Who are the decision-makers at PharmEnable?
Fundz holds 1 contact at PharmEnable. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology and Health Care around the same time

Companies in the same sectors as PharmEnable that raised within 45 days of this round, from Fundz verified event records.

  • SpyGlass Pharma, Inc. raised $40M on July 6, 2023.
  • Ocelot Bio raised $3M on July 6, 2023.
  • TolerogenixX raised $13M (Series A) on July 6, 2023.
  • Append Medical raised $4.3M (Series A) on July 6, 2023.
  • Reyedar raised $3.2M (Seed) on July 5, 2023.
  • MapLight Therapeutics raised $50M on July 5, 2023.

Who to call at PharmEnable, and when

A new round usually means PharmEnable is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day PharmEnable raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at PharmEnable, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at PharmEnable. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

PharmEnable

Location

Cambridge, Maryland, United States

About

PharmEnable is a Cambridge (UK) based drug discovery company, using a combination of medicinal chemistry and AI computational approaches to design the next generation of specific and cost-efficient small molecule drugs. Our mission is to discover new treatments for otherwise undruggable conditions. CEO Dr Hannah Sore is a medicinal chemist by background, and has worked across academia and pharma, as well as having a successful business consulting career. In 2012, after being seriously ill from sepsis, Dr Sore left her consulting career to dedicate herself to creating new medicines. She assembled a team of Cambridge scientists and entrepreneurs, in order to create innovative solutions to some of the biggest healthcare challenges. The PharmEnable platform focuses on creating chemical diversity, making potential new medicines that are 3-dimensional (3D) and inspired by nature. This innovative approach has all the advantages of small molecule drugs, in that the molecules can be produced cost efficiently in large quantities and taken by patients orally. In addition, the 3D structures make the molecules more specific and less likely to be toxic, opening up new possibilities for treating otherwise undruggable conditions.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment PharmEnable raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for PharmEnable's next move

See what Strategic adds

PharmEnable raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.